Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

This report describes a patient with ALK-rearranged non-small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a prolonged response to crizotinib and who has been treated successfully with a second-generation ALK inhibitor alone for >15...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Ou, Sai-Hong Ignatius, Sommers, Karen R., Azada, Michele C., Garon, Edward B.
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2015
Sujets:
Brief Communications
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319629/
https://ncbi.nlm.nih.gov/pubmed/25568147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0309
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires